The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
January 13th 2025
Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
1.0 Credit / Oncology, Hematology, Hematologic Cancer
View More
TKI Selection in CML: Clinical, Economic Burden and Long-term Outcomes
June 18th 2021Two posters presented at the European Hematology Association 2021 Virtual Congress evaluated tyrosine kinase inhibitor (TKI) selection in the front line and compared first-generation to second-generation TKIs.
Read More
Adding Zanubrutinib, Lenalidomide to R-CHOP May Benefit High-Risk Patients With DLBCL
June 12th 2021High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone).
Read More
Rajat Bannerji, MD, PhD, Chief, Section of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, speaks on the efficacy and safety findings of the CAPTIVATE study examining the fixed-duration regimen of ibutinib and venetoclax combination therapy in CLL.
Watch
Dr Christopher Arendt on OPTIC Findings for Dose Optimization of Ponatinib in Patients With CP-CML
June 5th 2021Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on efficacy and safety findings of the OPTIC study examining dose optimization of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to second-generation tyrosine kinase inhibitor therapy.
Watch
Latest in Leukemia and Lymphoma: AYA Overall Survival and Rituximab Responses
May 30th 2021New studies evaluate the impact of age on overall survival in adolescents and young adults (AYAs) with chronic lymphocytic leukemia, as well as response rates of rituximab in 2 combination regimens for hairy-cell leukemia and follicular lymphoma.
Read More
Tomivosertib Alone, in Combination Shows Promise in AML, Say Researchers
May 28th 2021The exploration of the MAPK pathway has come as researchers look for new therapeutic targets for acute myeloid leukemia (AML), which still faces resistance to novel treatments like FLT3 inhibitors and subsequent relapses.
Read More
Significant HCRU and Cost Burden for Patients With AML Who Relapse
May 26th 2021Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.
Read More
Oncologists Highlight Treatment, Patient Attributes That Impact Decision-making for CLL
May 22nd 2021With a variety of treatments available for chronic lymphocytic leukemia (CLL), a disease that is extremely heterogeneous, clinicians are faced with a challenging task to choose the right treatment for a patient.
Read More
Off-the-Shelf Antiviral T Cells Can Treat Painful Complication After Stem Cell Transplants
May 8th 2021BK virus–specific T cells from healthy donors were an effective and safe off-the-shelf treatment for patients with leukemia or lymphoma who developed a painful and common complication after allogeneic hematopoietic stem cell transplantation.
Read More
Umbralisib Carries Tolerability, Cost Benefits in Follicular Lymphoma, Says Research
May 7th 2021Through matching-adjusted indirect comparison, the authors of the abstract compared the use of umbralisib with other PI3Kis in this setting and found that the treatment yielded the lowest discontinuation rates due to adverse events (AEs), had a lower AE management cost burden, and achieved better duration of responses.
Read More
Diet, Exercise Enhance Effects of Chemotherapy, Odds of Survival for Youth With ALL
April 9th 2021Patients who cut their calorie intake by at least 10% and exercised modestly were 70% less likely to have remaining leukemic cells in their bone marrow 1 month after starting chemotherapy, according to results of an early study.
Read More
Emerging Options May Help Address Challenges With Traditional BTK-Inhibitor Treatment in Lymphomas
April 3rd 2021Reversible Bruton tyrosine kinase (BTK) inhibitors may play a key role in treatment when it comes to addressing resistance stemming mutations in the active site (Cys481) that emerge from treatment with irreversible BTK inhibitors.
Read More
Differentiating Between MCL, DLBCL May Require Additional Testing, Case Study Says
April 3rd 2021Classical mantle cell lymphoma (MCL) and 2 aggressive variants exhibited similar rates of negativity for the CD5 marker, but further testing may be needed in certain cases to avoid misdiagnosis with diffuse large B-cell lymphoma (DLBCL).
Read More
Reasons for COVID-19 Vaccine Hesitancy in Patients With Blood Cancer Are Complex
March 19th 2021A survey released this month of US patients with blood cancers shows a somewhat surprising level of hesitancy about receiving a COVID-19 vaccine, but because patients with cancer were not included in clinical trials, the situation for this population is somewhat nuanced.
Read More
Allo-SCT, MRD Negativity Associated With Better Outcomes in AML With Certain Mutations
March 15th 2021Study findings shed a light on the role of minimal residual disease (MRD) status and type of postremission therapy in the prognosis of patients with intermediate-risk acute myeloid leukemia (AML) who do not have FLT3-ITD, NPM1, and biallelic CEBPA mutations.
Read More